Mainstream media is GO, page-19

Lastly we should have that info in the not too distant future, we are just waiting on the ethics committee approval for the last couple of patients.

The question below was asked and answered directly after the the Phase One top Line Results Presentation.
here https://investorhub.pharmaust.com/announcements/6219218

09:17AM 01/03/2024

Dr Thurn thankyou for the fantastic presentation.

My question is about the patients.

All 12 have chosen to continue to take Monepantel on compassionate grounds which is also fantastic, my best wishes are with them. It would give us a fair indication on how they have been going if the start point on the Rate of Decline of ALSFRS-R chart (slide5) for the new Fight MND open ended trial was available.

Are you able to share that info.

Paul

PharmAust

ASX:PAA

01:20PM 01/03/2024

Hi Paul, Thanks for your question. The Open-label extension study is not funded by FightMND as it falls outside of its current funding opportunities. PharmAust is fully-funding that study. We will approach FightMND for further supplemental support given its success. In terms of supplying the start point for their ALSFRS-R score we can certainly look into that once all patients have been successfully enrolled into the study as the average score. Cheers Michael